Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC lowered its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 28.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,091 shares of the specialty pharmaceutical company's stock after selling 5,942 shares during the period. Gotham Asset Management LLC's holdings in Jazz Pharmaceuticals were worth $1,858,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $25,000. Quadrant Capital Group LLC grew its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares during the period. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $28,000. Allianz SE purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $29,000. Finally, Jones Financial Companies Lllp grew its holdings in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 130 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on JAZZ shares. Needham & Company LLC reissued a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler reissued an "overweight" rating and set a $147.00 target price (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Stock Up 2.7%

JAZZ opened at $108.98 on Friday. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $6.72 billion, a P/E ratio of 15.35, a P/E/G ratio of 1.04 and a beta of 0.38. The stock's 50 day moving average price is $115.73 and its 200 day moving average price is $121.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm's revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.68 earnings per share. As a group, research analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the transaction, the chief executive officer now owns 439,307 shares in the company, valued at $51,113,369.45. This represents a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,236 shares of company stock valued at $3,956,190. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.